Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) FCF Margin (2022 - 2025)

Century Therapeutics (IPSC) has disclosed FCF Margin for 4 consecutive years, with 32.15% as the latest value for Q1 2025.

  • On a quarterly basis, FCF Margin rose 356867.0% to 32.15% in Q1 2025 year-over-year; TTM through Sep 2025 was 99.71%, a 414334.0% increase, with the full-year FY2024 number at 1673.84%, up 289368.0% from a year prior.
  • FCF Margin was 32.15% for Q1 2025 at Century Therapeutics, up from 580.47% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 7840.93% in Q1 2022 to a low of 28046.46% in Q2 2023.
  • A 4-year average of 5233.98% and a median of 3579.38% in 2024 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: tumbled -2544732bps in 2023, then soared 2446709bps in 2024.
  • Century Therapeutics' FCF Margin stood at 10033.21% in 2022, then decreased by -1bps to 10152.99% in 2023, then soared by 94bps to 580.47% in 2024, then surged by 94bps to 32.15% in 2025.
  • Per Business Quant, the three most recent readings for IPSC's FCF Margin are 32.15% (Q1 2025), 580.47% (Q4 2024), and 3581.8% (Q3 2024).